^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AiRuiKa (camrelizumab)

    i
    Other names: INCSHR1210, SHR-1210, HR-301210, INCSHR-1210, SHR1210, HR301210, HR 301210, INCSHR 1210, SHR 1210
    Company:
    CG Invites, Elevar Therapeutics, HLB Bio Group, Jiangsu Hengrui Pharma, NPO Petrovax
    Drug class:
    PD1 inhibitor
    Related drugs:
    5d
    Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non-Small Cell Lung Cancer. (PubMed, Oncology (Williston Park))
    Although survival outcomes were comparable among the 3 PD-1 inhibitors in the overall cohort, tislelizumab and sintilimab showed superior PFS in PD-L1-positive subgroups, suggesting biomarker-driven therapeutic selection. These findings underscore the importance of PD-L1 status in optimizing immunotherapy regimens for advanced NSCLC, offering clinical insights for personalized treatment strategies.
    Clinical • Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)
    5d
    FUSCC Refractory TNBC Platform Study (FUTURE2.0) (clinicaltrials.gov)
    P2, N=120, Recruiting, Fudan University
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    everolimus • AiRuiKa (camrelizumab) • trastuzumab rezetecan (SHR-A1811) • famitinib (SHR 1020)
    6d
    Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients (clinicaltrials.gov)
    P2, N=41, Completed, Fudan University | Active, not recruiting --> Completed
    Trial completion
    |
    Erbitux (cetuximab) • cisplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel
    6d
    Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (clinicaltrials.gov)
    P2, N=39, Recruiting, Peking Union Medical College | Trial primary completion date: Jul 2026 --> Jul 2028
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    carboplatin • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Piqray (alpelisib) • Irene (pyrotinib) • albumin-bound paclitaxel • abiraterone acetate • fulvestrant • Aidixi (disitamab vedotin) • exemestane • Padcev (enfortumab vedotin-ejfv) • bicalutamide • Kaitanni (cadonilimab) • goserelin acetate • Qibeian (iparomlimab/tuvonralimab) • Yidafan (ivonescimab) • iparomlimab (QL1604) • leuprolide acetate for depot suspension • Entyvio (vedolizumab)
    6d
    Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, West China Hospital | Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Feb 2027 | Trial primary completion date: Oct 2025 --> Jun 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Ibrance (palbociclib) • AiRuiKa (camrelizumab)
    6d
    Neoadjuvant mFOLFOX6 plus camrelizumab and apatinib in colon cancer and biomarker research via spatiotemporal-omics profiling. (PubMed, NPJ Precis Oncol)
    An increase in the frequency of CD8 + T-cells and a decreased frequency of tissue-resident memory 1 (Trm-1) and regulatory T (Treg) cells are associated with a favorable response to neoadjuvant therapy. Spatiotemporal multiomics analysis highlighted tissue-resident macrophages as potential predictive biomarkers and warrants further verification.
    Journal • PD(L)-1 Biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    5-fluorouracil • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin • leucovorin calcium
    6d
    Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    carboplatin • paclitaxel • AiRuiKa (camrelizumab) • AiSuDa (ivarmacitinib)
    7d
    Long-term survival in a patient with non-small cell lung cancer harboring KRAS G13C and TP53 co-mutations: case report and literature review. (PubMed, Front Med (Lausanne))
    The patient received first-line and maintenance therapy comprising carboplatin/pemetrexed, camrelizumab, and Endostar/bevacizumab...Our findings suggest that the combination of chemotherapy, immunotherapy, and anti-angiogenic agents may represent a viable therapeutic strategy for patients with KRAS G13C/TP53 co-mutated NSCLC. This case report suggests a potentially promising therapeutic strategy to improve long-term survival in this difficult-to-treat patient population.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53)
    |
    TP53 mutation • KRAS mutation • KRAS G13
    |
    Avastin (bevacizumab) • carboplatin • AiRuiKa (camrelizumab) • pemetrexed • Endostar (recombinant human endostatin)
    8d
    Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line (clinicaltrials.gov)
    P2, N=80, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tyvyt (sintilimab) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • Stivarga (regorafenib)
    15d
    A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer (clinicaltrials.gov)
    P=N/A, N=43, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    carboplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    19d
    Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases (CAPLocal) : A Multicentre, Single-Arm,Prospective Cohort Study (clinicaltrials.gov)
    P=N/A, N=32, Not yet recruiting, Xiangya Hospital of Central South University
    New trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    22d
    Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=80, Suspended, wang shusen | Trial completion date: Dec 2026 --> Dec 2027 | Recruiting --> Suspended | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial completion date • Trial suspension • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    AiRuiKa (camrelizumab) • AiRuiYi (fluzoparib)